Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic

JAMA

Volumn 281, Issue 11, 1999, Pages 1014-1018

  Nolan, Charles M ^a,b,c   Goldberg, Stefan V ^a,b   Buskin, Susan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0033577290     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.11.1014     Document Type: Article

References (34)

1. American Thoracic Society. Chemoprophylaxis for the prevention of tuberculosis. Am Rev Respir Dis. 1965; 96:558-560.
2. Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med. 1990;150: 2517-2522.
3. Sarasin FP, Perrier A, Rochat T. Isoniazid preventive therapy for pulmonary tuberculosis sequclae: which patients up to which age? Tuber Lung Dis 1995;76: 394-400
4. Jordan TJ, Lewit EM, Reichman LB. Isoniazid preventive therapy for tuberculosis: decision analysis considering ethnicity and gender. Am Rev Respir Dis. 1991; 144:1357-1360.
5. Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest 1992; 101:1298-1301.
6. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978; 117:991-1001.
7. Riska N. Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuber Lung Dis. 1976;51:203-208.
8. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975;69:289-302.
9. Garabaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis - report of an outbreak. Am Rev Respir Dis. 1972;106:357-364.
10. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;333:1118-1127.
11. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med. 1976;84: 181-192.
12. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-1374.
13. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med. 1993; 159:560-564.
14. Millard PS, Wiscosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med. 1996;164:486-491.
15. Comstock CW. Evaluating isoniazid preventive therapy. Ann Intern Med. 1981;94:817-819.
16. Iseman MD, Miller B. If a tree falls in the middle of the forest. Am Rev Respir Dis. 1989;140:575-576.
17. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths. Am Rev Respir Dis. 1992;145:494-497.
18. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest. 1991;99:465-471.
19. Dickinson DS, Bailey WC, Hirschowitz BI, et al. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol. 1981;3:271-279.
20. Leff DR, Leff AR. Tuberculosis control policies in major metropolitan health departments in the United States. Am J Respir Crit Care Med. 1997;156:1487-1494.
21. Franks AL, Binkin NJ, Snider DE Jr, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104:151-155.
22. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis. 1989;140:700-705.
23. Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med. 1981;94:808-813.
24. Rose DN, Schecter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA. 1986;256: 2709-2713.
25. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215-220.
26. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age. Ann Intern Med. 1997;127:1051-1061.
27. Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 1989;(suppl S-3):1-25.
28. Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997;278:304-307.
29. McCray E, Weinbaum CM, Braden CR, Onorato IM. The epidemiology of tuberculosis in the United States. Clin Chest Med. 1997;18:99-113.
30. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801-808.
31. Halsey NA, Coberly JS, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351:786-792.
32. Gordin F, Chaisson R, Matts J, et al. A randomized trial of 2 months of rifampin and pyrazinamide versus 12 months of isoniazid for the prevention of tuberculosis in HIV-positive, PPD+ patients. In: Program and Abstracts, Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill.
33. Mwinga AG, Hosp M, Godfrey-Faussett P, et al. Randomized placebo controlled trial of two intermittent regimens in the prevention of HIV-related tuberculosis in Lusake, Zambia. Int J Tuberc Lung Dis. 1997; 1(suppl 1):S164.
34. Miller B, Castro KG. Sharpen available tools for tuberculosis control, but new tools needed for elimination. JAMA. 1996;276:1916-1917.